A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.
Fiche publication
Date publication
septembre 2021
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUIHARD Sébastien
Tous les auteurs :
Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J
Lien Pubmed
Résumé
A Benchmark Case (BC) was performed as part of the quality assurance process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of multisite stereotactic radiation therapy (SBRT) alone in oligometastatic head and neck squamous cell carcinoma (HNSCC) as an alternative to systemic treatment and SBRT.
Mots clés
Assurance qualité, Benchmark case, Cancer, Clinical trial, Deviation, Déviation, Essai clinique, Head and neck, ORL, Quality assurance, Radiothérapie stéréotaxique, Stereotactic radiotherapy
Référence
Cancer Radiother. 2021 Sep 23;: